Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
  • Policy / Pricing

Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026

KFF Medicare

The Medicare Part D program provides an outpatient prescription drug benefit to 56 million older adults and people with long-term disabilities in Medicare who enroll in private plans.

Read full story

pharminent June 11, 2026 (Last updated: June 19, 2026)

KFF Medicare

The Medicare Part D program provides an outpatient prescription drug benefit to 56 million older adults and people with long-term disabilities in Medicare who enroll in private plans.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs
Next: How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

Related Stories

  • Policy / Pricing

US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028

pharminent July 22, 2026
  • Policy / Pricing

UK commits to pharma IP protection in Swiss trade deal

pharminent July 16, 2026
  • Policy / Pricing

Germany approves healthcare costs overhaul despite significant pharma opposition

pharminent July 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.